11.30 USD
↘ 0.01 (0.09%)AT CLOSE (11:59 AM EDT)
Corbus Pharmaceuticals Holdings, Inc.
CRBPNASDAQ • USD
11.34
↗ 0.04 (0.31%)
POST MARKET (AS OF 07:30 PM EDT)
Post Market
AS OF 07:30 PM EDT
11.34
↗ 0.04 (0.31%)
Market: CLOSED
Shares of Corbus Pharmaceuticals Holdings, Inc. (CRBP) are trading at $11.31. CRBP shows a split signal: technical indicators suggest "Strong Buy" while underlying fundamentals indicate "Sell". This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation metrics suggest CRBP is trading at a discount to its peers, earning an "Attractively Valued" rating.
Technical & fundamental data as of Aug 26, 2026.
Open?$11.36
High?$11.55
Low?$10.96
Prev. Close?$11.31
Volume?392.2K
Avg. Volume?399.9K
VWAP?$11.29
Rel. Volume?0.98x
Bid / Ask
Bid?$11.11 × 200
Ask?$11.35 × 300
Spread?$0.24
Midpoint?$11.23
Valuation & Ratios
Market Cap?218.6M
Shares Out?18.7M
Float?15.9M
Float %?89.7%
P/E Ratio?N/A
P/B Ratio?2.14
EPS?-$5.27
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Themes
Employees
36
Market Cap
218.8M
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2014-10-24
Address
500 RIVER RIDGE DRIVE
NORWOOD, MA 02062
Phone: 617-963-0103
NORWOOD, MA 02062
Phone: 617-963-0103
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?50
Short Sent.?59
Piotroski F-Score?0/9Weak
Altman Z-Score?-3.28Distress
Confidence?51%Low
Short InterestHigh
Short % of Float?13.50%High
Short Interest?2.1M
Days to Cover?6.0
Free Float15.9M
Avg Daily Volume355.5K
Settlement Date2026-08-14
Financial Health
Current Ratio?5.71Strong
Quick Ratio?5.71Strong
Cash Ratio?1.09Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?2.14CHEAP▾
Peers100
S&P71
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-1.8CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-99.7%WEAK▾
S&P3
ROA?-80.3%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-86687000
Enterprise Value?$195.2M
Fundamentals ratios updated end of day